Alcala-Diaz, Juan FLimia-Perez, LauraGomez-Huelgas, RicardoMartin-Escalante, Maria DCortes-Rodriguez, BegoñaZambrana-Garcia, Jose LEntrenas-Castillo, MartaPerez-Caballero, Ana ILopez-Carmona, Maria DGarcia-Alegria, JavierLozano-Rodriguez-Mancheño, AquilesArenas-de Larriva, Maria Del SolPerez-Belmonte, Luis MJungreis, IrwinBouillon, RogerQuesada-Gomez, Jose ManualLopez-Miranda, Jose2023-02-092023-02-092021-05-21Alcala-Diaz JF, Limia-Perez L, Gomez-Huelgas R, Martin-Escalante MD, Cortes-Rodriguez B, Zambrana-Garcia JL, et al. Calcifediol Treatment and Hospital Mortality Due to COVID-19: A Cohort Study. Nutrients. 2021 May 21;13(6):1760http://hdl.handle.net/10668/17870Calcifediol has been proposed as a potential treatment for COVID-19 patients. To compare the administration or not of oral calcifediol on mortality risk of patients hospitalized because of COVID-19. Retrospective, multicenter, open, non-randomized cohort study. Hospitalized care. Patients with laboratory-confirmed COVID-19 between 5 February and 5 May 2020 in five hospitals in the South of Spain. Patients received calcifediol (25-hydroxyvitamin D3) treatment (0.266 mg/capsule, 2 capsules on entry and then one capsule on day 3, 7, 14, 21, and 28) or not. In-hospital mortality during the first 30 days after admission. A total of 537 patients were hospitalized with COVID-19 (317 males (59%), median age, 70 years), and 79 (14.7%) received calcifediol treatment. Overall, in-hospital mortality during the first 30 days was 17.5%. The OR of death for patients receiving calcifediol (mortality rate of 5%) was 0.22 (95% CI, 0.08 to 0.61) compared to patients not receiving such treatment (mortality rate of 20%; p 7 mmol/L, respiratory rate ≥ 30/min, systolic blood pressure Among patients hospitalized with COVID-19, treatment with calcifediol, compared with those not receiving calcifediol, was significantly associated with lower in-hospital mortality during the first 30 days. The observational design and sample size may limit the interpretation of these findings.enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/COVID-19COVID-19 drug treatmentSARS-CoV-2CalcifediolVitamin DAgedAged, 80 and overCOVID-19CalcifediolFemaleHospital mortalityHumansMaleMiddle agedRetrospective studiesSARS-CoV-2Severity of illness indexCOVID-19 drug treatmentresearch article34064175open accessMortalidad hospitalariaPersona de mediana edadTratamiento farmacológico de COVID-19Índice de severidad de la enfermedad10.3390/nu130617602072-6643PMC8224356https://www.mdpi.com/2072-6643/13/6/1760/pdf?version=1621996707https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8224356/pdf